Beyer Pat 4

What Happened

• Pat Beyer, President & CEO of CONMED Corp (CNMD), received a grant of 28,145 restricted stock units (RSUs) reported as a derivative award on April 1, 2026. The Form 4 shows an acquisition at $0.00 (code A – award/grant); the board approved the award as an additional equity grant with a target value of $1.0 million.

Key Details

• Transaction date: 2026-04-01 (reported on Form 4 filed 2026-04-02). Transaction code: A (award/grant). Reported price: $0.00 (derivative RSU grant).
• Shares/units granted: 28,145 RSUs. Reported dollar value on Form 4: $0; target grant value per footnote: $1,000,000.
• Vesting schedule: Vesting begins April 1, 2026, in three equal annual tranches over 3 years.
• Post‑vest restriction: A 2‑year holding period applies to net after‑tax shares following each vesting event (per footnote).
• Shares owned after transaction: Not specified in this filing.
• Timeliness: Filing was submitted the next day (not indicated as late).

Context

• This is a compensation award (RSUs) rather than an open‑market purchase or sale; such grants are common for executives and reflect company compensation decisions rather than immediate buying/selling sentiment. The 2‑year post‑vest holding requirement limits immediate sales of vested shares.